MedPath

Novel Trivalent COVID-19 Vaccine Shows Robust Cross-Protection Against XBB Variants

Researchers have developed a new trivalent recombinant protein vaccine (Tri-Vac) that demonstrates strong cross-neutralization against multiple SARS-CoV-2 variants, including the challenging XBB lineages. The vaccine, which combines RBD sequences from Delta, BA.5, and XBB.1.5 variants, showed promising results in both animal studies and initial human trials, with good safety profile and ability to boost neutralizing antibodies when used as a heterologous booster.

A team of researchers has developed a novel trivalent recombinant protein vaccine that shows promising results in generating broad protection against multiple SARS-CoV-2 variants, including the immune-evasive XBB lineages.

Innovative Vaccine Design and Development

The new vaccine, dubbed Tri-Vac, incorporates receptor-binding domain (RBD) sequences from three different SARS-CoV-2 variants - Delta, BA.5, and XBB.1.5 - in a 1:1:4 ratio. The vaccine's design features a self-assembled trimeric protein structure that clusters three RBD molecules on one side and HR1/HR2 helices on the other, creating a distinctive bouquet-like shape.

Robust Preclinical Results

In mouse studies, Tri-Vac demonstrated several key advantages:
  • Generated high levels of RBD-specific IgG with endpoint titers exceeding 106
  • Induced broad-spectrum neutralizing antibodies against multiple variants
  • Provided effective protection against live XBB.1.16 challenge
  • Stimulated robust cellular immune responses and germinal center activity
The vaccine showed particular effectiveness when used as a heterologous booster following initial vaccination with either inactivated or mRNA vaccines, significantly improving neutralization against XBB variants.

Promising Human Trial Outcomes

In a Phase 1 investigator-initiated trial involving 64 participants:
  • Both low (30μg) and high (60μg) doses were well-tolerated
  • Minimal adverse events reported, mostly mild and transient
  • Significant boost in neutralizing antibodies against multiple variants
  • Neutralizing activity maintained for over six months
  • Effective against recent variants including BA.2.86 and JN.1
The GMT of neutralizing antibodies increased substantially across all tested variants, with particularly impressive improvements against XBB lineages. For instance, in the high-dose group, neutralization against XBB.1.5 increased 16.3-fold compared to pre-vaccination levels.

Safety Profile

The vaccine demonstrated an excellent safety profile in human trials:
  • Only 25% of high-dose and 18.75% of low-dose recipients reported mild adverse events
  • Most common side effect was injection site pain
  • No serious adverse events reported within 6 months of vaccination

Long-term Protection

Follow-up studies at six months post-vaccination showed:
  • Maintained neutralizing activity in both dosage groups
  • Sustained protection against XBB.1.5 and JN.1 variants
  • GMTs exceeding 800 against XBB.1.5 and 600 against JN.1
This new vaccine platform represents a significant advancement in COVID-19 vaccine development, particularly in addressing the challenge of variant escape. Its ability to generate broad neutralizing responses and function effectively as a heterologous booster makes it a promising candidate for future vaccination strategies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

BioNTech's Bispecific Antibody BNT-327 Shows Promise in Triple-Negative Breast Cancer

BioNTech's BNT-327, a bispecific antibody targeting PD-L1 and VEGF, has demonstrated positive early results in patients with triple-negative breast cancer.
The bispecific antibody builds on the success of checkpoint inhibitors like Keytruda, potentially representing the next generation of immunotherapy drugs.

TNBC Vaccine Shows Promising Immune Response and Safety in Phase 1 Trial

A Phase 1 trial of an investigational vaccine for triple-negative breast cancer (TNBC) demonstrated promising safety and immune activation across all patient cohorts.
Over 70% of patients exhibited protocol-defined immune responses, with injection site irritation being the primary adverse event and no major systemic adverse events observed.

Biktarvy Demonstrates Sustained Efficacy and Safety in HIV/HBV Co-infection Over Three Years

The ALLIANCE Phase III study demonstrated that Biktarvy (TAF-based regimen) achieved 99% HIV-1 RNA suppression and 80.2% HBV DNA suppression at Week 144 in HIV/HBV co-infected adults.
The TAF-based regimen showed superior Hepatitis B outcomes, including higher rates of HBeAg seroconversion, ALT normalization, and S antigen loss, compared to TDF-based regimens.

Combination Therapies Show Promise for Functional Cure of Chronic Hepatitis B

A Phase II trial of xalnesiran plus immunomodulators showed significant hepatitis B surface antigen (HBsAg) loss in patients with chronic HBV infection.
VTP-300 combined with low-dose nivolumab demonstrated sustained HBsAg reductions, meeting functional cure criteria in a Phase 2b trial.

Cleveland Clinic Presents Promising Data on Triple-Negative Breast Cancer Vaccine

Cleveland Clinic researchers presented updated findings on their vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
The Phase 1 clinical trial showed the investigational vaccine was generally well tolerated and produced an immune response in most patients across three cohorts.

Cleveland Clinic's Breast Cancer Vaccine Shows Promising Immune Response in Phase 1 Trial

Cleveland Clinic researchers presented updated findings from their Phase 1 study of a preventive vaccine for triple-negative breast cancer, the most aggressive form of the disease.
The investigational vaccine was generally well tolerated and stimulated an immune response in most patients, according to the study team's findings presented at the Society for Immunotherapy of Cancer Annual Meeting.

Mosaic-8b Nanoparticle Vaccine Shows Promise Against Sarbecovirus Variants

A novel mosaic-8b nanoparticle vaccine is under development to provide broad cross-reactive immunity against known and future sarbecovirus strains, enhancing pandemic preparedness.
The vaccine targets conserved regions of the receptor-binding domain (RBD) shared by all SARS-like betacoronaviruses, aiming to overcome the limitations of current vaccines due to viral mutations.

MinervaX and Wacker Biotech Collaborate to Advance Group B Streptococcus Vaccine Production

MinervaX and Wacker Biotech collaborate to scale up manufacturing of MinervaX's novel protein-only vaccine against Group B Streptococcus (GBS) in preparation for Phase III trials.
Wacker Biotech will handle technology transfer, process validation, and commercial manufacturing of the vaccine's active protein ingredients at its Amsterdam facility.

COVID-19 Vaccine Landscape: mRNA and DNA Vaccine Efficacy and Development

mRNA vaccines like Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273 have demonstrated high efficacy (72-95%) against moderate-to-severe COVID-19 in adults, with ongoing studies evaluating their effectiveness against emerging variants.
DNA vaccines, including Zydus Cadila's ZyCov-D, have shown promise with good safety profiles and the ability to induce neutralizing antibodies and cellular immune responses, offering a cost-effective alternative, especially in developing countries.

Phase 2/3 Study Shows Robust Immunogenicity of NVX-CoV2601 in Vaccine-Naive Individuals with Prior SARS-CoV-2 Infection

A phase 2/3 open-label study demonstrates that a single dose of the monovalent XBB.1.5 vaccine, NVX-CoV2601, elicits robust immunogenicity in vaccine-naive individuals with prior SARS-CoV-2 infection, comparable to those previously vaccinated with mRNA vaccines. The study, involving participants across 30 US sites, found no new safety signals and supports the use of single doses of NVX-CoV2601 for immunity against SARS-CoV-2, regardless of prior vaccination history.

Reference News

[1]
Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and ...
nature.com · Dec 30, 2024

The study developed trimeric proteins RBDBA.5-HR and RBDXBB.1.5-HR, linking RBD sequences with HR1 and HR2, showing a bo...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy